C-Terminal fragment of adiponectin receptor clinical correlations

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre- diabetic assessment (n = 240). Patients with infl ammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies(n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10)were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) andimpaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and infl ammation. Patients using anti- TNF átherapies (Remicade® Infl iximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without signifi cant weight changes andthe within patient variability was 10 %. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 % sensitivity and 93 % specifi city. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive valuecriteria. Only 10 % of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.

Original languageEnglish (US)
Title of host publicationInflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates
PublisherSpringer International Publishing
Pages111-126
Number of pages16
ISBN (Print)9783319219271, 9783319219264
DOIs
StatePublished - Jan 1 2015

Fingerprint

Adiponectin Receptors
Glucose
Medical problems
Immunosuppressive Agents
Glucose Tolerance Test
Pancreatic Neoplasms
Immunoassay
Liver
Liver Diseases
Fasting
Healthy Volunteers
Blood
Tumor Necrosis Factor-alpha
Earth (planet)
Breast Neoplasms
Plasmas
Weights and Measures
Therapeutics
Serum
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Vella, A. (2015). C-Terminal fragment of adiponectin receptor clinical correlations. In Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates (pp. 111-126). Springer International Publishing. https://doi.org/10.1007/978-3-319-21927-1_6

C-Terminal fragment of adiponectin receptor clinical correlations. / Vella, Adrian.

Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates. Springer International Publishing, 2015. p. 111-126.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vella, A 2015, C-Terminal fragment of adiponectin receptor clinical correlations. in Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates. Springer International Publishing, pp. 111-126. https://doi.org/10.1007/978-3-319-21927-1_6
Vella A. C-Terminal fragment of adiponectin receptor clinical correlations. In Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates. Springer International Publishing. 2015. p. 111-126 https://doi.org/10.1007/978-3-319-21927-1_6
Vella, Adrian. / C-Terminal fragment of adiponectin receptor clinical correlations. Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates. Springer International Publishing, 2015. pp. 111-126
@inbook{5d532e771b64408db9e407c3c4255282,
title = "C-Terminal fragment of adiponectin receptor clinical correlations",
abstract = "The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre- diabetic assessment (n = 240). Patients with infl ammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies(n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10)were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) andimpaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and infl ammation. Patients using anti- TNF {\'a}therapies (Remicade{\circledR} Infl iximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without signifi cant weight changes andthe within patient variability was 10 {\%}. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 {\%} sensitivity and 93 {\%} specifi city. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive valuecriteria. Only 10 {\%} of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.",
author = "Adrian Vella",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-21927-1_6",
language = "English (US)",
isbn = "9783319219271",
pages = "111--126",
booktitle = "Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - C-Terminal fragment of adiponectin receptor clinical correlations

AU - Vella, Adrian

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre- diabetic assessment (n = 240). Patients with infl ammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies(n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10)were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) andimpaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and infl ammation. Patients using anti- TNF átherapies (Remicade® Infl iximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without signifi cant weight changes andthe within patient variability was 10 %. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 % sensitivity and 93 % specifi city. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive valuecriteria. Only 10 % of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.

AB - The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre- diabetic assessment (n = 240). Patients with infl ammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies(n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10)were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) andimpaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and infl ammation. Patients using anti- TNF átherapies (Remicade® Infl iximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without signifi cant weight changes andthe within patient variability was 10 %. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 % sensitivity and 93 % specifi city. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive valuecriteria. Only 10 % of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.

UR - http://www.scopus.com/inward/record.url?scp=84956831179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956831179&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-21927-1_6

DO - 10.1007/978-3-319-21927-1_6

M3 - Chapter

SN - 9783319219271

SN - 9783319219264

SP - 111

EP - 126

BT - Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates

PB - Springer International Publishing

ER -